Logo image
Back
The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation
Journal article   Peer reviewed

The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation

M.A. Fabre, D.C. Jones, M. Bunce, P.J. Morris, P.J. Friend, K.I. Welsh and S.E. Marshall
Transplant International, Vol.17(9), pp.531-539
2004
DOI: https://doi.org/10.1111/j.1432-2277.2004.tb00483.x
url
Link to Published Version *Subscription may be requiredView

Abstract

Azathioprine metabolism is influenced by activity of the enzyme thiopurine S-methyltransferase (TPMT), which varies markedly between individuals. In this study we examined the influence of TPMT gene polymorphisms on azathioprine dose 1 year after renal transplantation. TPMT coding and promoter genotypes were determined using PCR-based assays. Azathioprine dose, white cell count, and intercurrent events throughout the first year after renal transplantation were ascertained from contemporaneous clinical notes. All patients analysed (n = 172) received an initial azathioprine dose of 1.5 mg/kg per day. Twelve individuals with one variant TPMT coding allele were detected (*3A n = 11, *3C n = 1). Of these, 58% required azathioprine dose reduction because of leucopenia, compared to only 30% of homozygous wild-type patients (P = 0.04). A significant correlation between the presence of ≥11 variable number tandem repeats (VNTRs) in the TPMT promoter and reduction in azathioprine dose was also identified (P = 0.001). We concluded that when azathioprine is administered at an initial dose of 1.5 mg/kg per day, both coding and promoter TPMT polymorphisms influence the dose tolerated.

Details

Metrics

29 Record Views
Logo image